Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01050478
Other study ID # CR015427
Secondary ID R076477SCH303820
Status Completed
Phase Phase 4
First received January 14, 2010
Last updated February 8, 2016
Start date March 2010
Est. completion date December 2011

Study information

Verified date February 2016
Source Janssen Cilag N.V./S.A.
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health ProductsBelgium: Ethics Committee
Study type Interventional

Clinical Trial Summary

This study will investigate the effect of paliperidone ER (in combination with or without benzodiazepines) in patients presenting with symptoms of agitation and/or aggression in the context of psychosis, and will generate data regarding both efficacy and safety in the acute setting.


Description:

Psychomotor agitation that requires hospitalization is a common event during the course of certain major psychiatric disorders, including schizophrenia. Emergency psychiatric services are the first doorway for the control of agitation and behavioural disturbances of the mentally ill in order to avoid dangerousness and aggression towards themselves and/or others. The use of drugs that influence the psychological behaviour (psychotropic drugs) should help to handle agitation and aggression, rapidly rendering people calm and/or sedated without producing distressing or dangerous adverse events, and facilitating extended assessment and definitive treatment. Oral atypical antipsychotics, alone or in combination with a benzodiazepine, are considered first line treatment for patients who present at the emergency ward with mild to moderate psychotic agitation. Paliperidone is a new atypical antipsychotic therapeutic agent for the treatment of schizophrenia. Paliperidone extended release (ER) might be considered as a treatment option for patients presenting with agitation and/or aggression (in combination with short term use of benzodiazepines) because of its fast onset of action and limited or no long term sedating effects. This open-label, single arm, multicenter, interventional descriptive study will collect data on efficacy and safety during first days of treatment with paliperidone ER in patients with acute agitation in the context of psychosis in the psychiatric emergency setting. The assessment of effectiveness/response will be based on Positive And Negative Syndrome Score Exciting Component (PANSS-EC) improvement. Safety evaluations include the incidence of serious and non-serious adverse events. The study will end after 5 days of treatment or at day of discharge from the hospital, whatever comes first. 6 mg (patients with an acute exacerbation of schizophrenia in a real-world setting an initial dose of paliperidone 9 mg once daily may provide optimal clinical efficacy with good tolerability) tablet, oral, once a day during the study duration (5 days).


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patient presenting with acute agitation and/or aggression in the context of psychosis, suspected schizophrenia PANSS-EC score >=20 Patient is outpatient in need of hospitalization female patients of childbearing potential must have a negative urine pregnancy test at baseline and further adequate anticonceptive protection signed informed consent

Exclusion Criteria:

Received benzodiazepines 4 hours prior to enrolment Received antipsychotic medication 72 hours prior to enrolment agitation, aggression or violent behaviour that necessitates the use of intramuscular or intravenous medication Patient's preference for intramuscular or intravenous medication Patient judged to be at high risk for suicidal behaviour Pregnant or breast feeding females Patient received clozapine or long-acting injectable antipsychotic during the last 3 months Serious unstable medical condition, including known clinically relevant lab abnormalities History of current symptoms or tardive dyskinesia History of neuroleptic malignant syndrome Participation in an investigational drug trial in the 30 days prior to selection Inability to swallow the study medication whole with the aid of water (chewing, dissolving, dividing or crushing the study medication is not allowed) Patients with a narrowing or blockage of their gastro-intestinal tract Patients with current or known history (past 6 months) of substance dependence according to DSM-IV criteria known hypersensitivity to paliperidone ER or risperidone Employees of the investigator or study centre, persons with direct involvement in the proposed study or other studies under the direction of that investigator or study centre, or family members of the employees or the investigator

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Paliperidone ER
paliperidone ER at 2 dosage levels (6 and 9 mg/day)
Benzodiazepine
Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Cilag N.V./S.A.

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Audenaert K, Godenir F, Geerts P, Van Gils L, Wouters C, Detraux J. IMPACT (Invega in the Management of Patients in the ACute seTting): results from a Belgian study using paliperidone extended-release in the management of psychotic patients with acute agi

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients having an improvement of 40% or more on PANSS-EC All of the 8 study visits during the 5-day study duration No
Secondary Assessing the change from baseline on PANSS-EC (Positive and Negative Syndrome Scale - Exciting Component) All of the 8 study visits during the 5-day study duration No
Secondary Assessing the change from baseline on the OAS (Overt Agression Scale) All of the 8 study visits during the 5-day study duration No
Secondary Assessing disease severity (Global Assessment of Functioning) All of the study visits during the 5-day study duration, except study visit 2 No
Secondary Assessing daytime drowsiness (Behaviour Activity Rating Scale) All of the 8 study visits during the 5-day study duration No
Secondary Assessing tolerability and safety by reporting adverse events and vital signs All of the 8 study visits during the 5-day study duration Yes
See also
  Status Clinical Trial Phase
Completed NCT03832257 - Improving Safety of Transitions to Skilled Nursing Care Using Videoconferencing N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT00186342 - Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT02568475 - Involving Nursing Home Residents and Their Families in Acute Care Transfer Decisions N/A
Terminated NCT00563654 - Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT00073372 - A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) Phase 3
Recruiting NCT05708768 - Digital, Innovative, Sustainable, and Knowledge-based Acute Municipal Healthcare Services Illness and Trauma
Completed NCT04571021 - Implementation of the Individual Danish Emergency Process Triage N/A
Completed NCT03982589 - Telomere Length in Relation to Acute Stress Response in Critical Care Patients
Suspended NCT04519086 - The Optimization of a Low-dose CT Protocol in Patients With Suspected Uncomplicated Acute Appendicitis and BMI >30 N/A
Recruiting NCT02688244 - Irrigation Versus Suction in Complicated Acute Appendicitis N/A
Completed NCT02474277 - How Well Does the 30-Second Chair Stand Test Predict Rehabilitation Needs in Acutely Admitted Elderly Patients N/A
Recruiting NCT02422901 - A Long-term Study to Describe the Use of PASCORBIN® 7.5 g in Patients With Vitamin C Deficiency
Completed NCT01278199 - Bronchial Artery Embolization and Medical Measures in Non Severe Acute Hemoptysis of Mild-moderate Abundance N/A
Recruiting NCT05506683 - Improving Nighttime Access to Care and Treatment; Part 2- Ghana N/A
Recruiting NCT06421246 - Activity in Geriatric Patients and Validation of the Danish Version of the Acute Care Mobility Assessment
Completed NCT02912624 - Simple Intensive Care Studies I (SICS-I)
Recruiting NCT02800122 - PAthwAy of Dyspneic patIent in Emergency (PArADIsE)
Completed NCT02915640 - Use of a Mobile Remote Device to Optimize Pediatric Inter-facility Transportation: A Feasibility Study N/A